These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38503370)

  • 21. Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice.
    Bamba R; Okamura T; Hashimoto Y; Majima S; Senmaru T; Ushigome E; Nakanishi N; Asano M; Yamazaki M; Takakuwa H; Hamaguchi M; Fukui M
    J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):574-588. PubMed ID: 34854254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment.
    Storgaard H; Bagger JI; Knop FK; Vilsbøll T; Rungby J
    Basic Clin Pharmacol Toxicol; 2016 Feb; 118(2):168-70. PubMed ID: 26291182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients-the role of antidiabetic and antihypertensive medications.
    Kitamura K; Hayashi K; Ito S; Hoshina Y; Sakai M; Yoshino K; Endo K; Fujitani S; Suzuki T
    Hypertens Res; 2021 May; 44(5):508-517. PubMed ID: 33311577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States.
    Sangha V; Lipska K; Lin Z; Inzucchi SE; McGuire DK; Krumholz HM; Khera R
    Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e008381. PubMed ID: 34779654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.
    Fleming N; Hamblin PS; Story D; Ekinci EI
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32302001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice.
    Atageldiyeva K; Fujita Y; Yanagimachi T; Mizumoto K; Takeda Y; Honjo J; Takiyama Y; Abiko A; Makino Y; Haneda M
    PLoS One; 2016; 11(6):e0157672. PubMed ID: 27327650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
    Lee DM; Battson ML; Jarrell DK; Hou S; Ecton KE; Weir TL; Gentile CL
    Cardiovasc Diabetol; 2018 Apr; 17(1):62. PubMed ID: 29703207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db/db mice.
    Gong Q; Zhang R; Wei F; Fang J; Zhang J; Sun J; Sun Q; Wang H
    Biomed Pharmacother; 2022 Aug; 152():113222. PubMed ID: 35671581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases.
    Goto S; Ishikawa JY; Idei M; Iwabuchi M; Namekawa M; Nomura T
    Am J Case Rep; 2021 Mar; 22():e929773. PubMed ID: 33723205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice.
    Hogan MF; Hackney DJ; Aplin AC; Mundinger TO; Larmore MJ; Castillo JJ; Esser N; Zraika S; Hull RL
    J Endocrinol; 2021 Feb; 248(2):95-106. PubMed ID: 33337344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice.
    Hata S; Okamura T; Kobayashi A; Bamba R; Miyoshi T; Nakajima H; Kitagawa N; Hashimoto Y; Majima S; Senmaru T; Okada H; Ushigome E; Nakanishi N; Takakuwa H; Sasano R; Hamaguchi M; Fukui M
    Nutrients; 2022 Aug; 14(17):. PubMed ID: 36079789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diet intake control is indispensable for the gluconeogenic response to sodium-glucose cotransporter 2 inhibition in male mice.
    Hashiuchi E; Watanabe H; Kimura K; Matsumoto M; Inoue H; Inaba Y
    J Diabetes Investig; 2021 Jan; 12(1):35-47. PubMed ID: 32515547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin.
    Saffo S; Kaplan DE; Mahmud N; Serper M; John BV; Ross JS; Taddei T
    Diabetes Obes Metab; 2021 Oct; 23(10):2402-2408. PubMed ID: 34227216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study.
    DeRemer CE; Vouri SM; Guo J; Donahoo WT; Winterstein AG; Shao H
    J Diabetes Complications; 2021 Sep; 35(9):107972. PubMed ID: 34247911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
    Bonora BM; Avogaro A; Fadini GP
    Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved Glycaemic Control and Nephroprotective Effects of Empagliflozin and Paricalcitol Co-Therapy in Mice with Type 2 Diabetes Mellitus.
    Mujalli A; Farrash WF; Obaid AA; Khan AA; Almaimani RA; Idris S; Elzubier ME; Khidir EBA; Aslam A; Minshawi F; Alobaidy MA; Alharbi AB; Almasmoum HA; Ghaith M; Alqethami K; Refaat B
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use.
    Laursen HVB; Røikjer JB; Dal J; Jensen MH
    Curr Drug Saf; 2021; 16(1):73-81. PubMed ID: 32814538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
    Menghoum N; Oriot P; Hermans MP; Mariage JL
    Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.